Skip to main content
. Author manuscript; available in PMC: 2024 Jul 10.
Published in final edited form as: Gynecol Oncol. 2022 Nov 18;168:92–99. doi: 10.1016/j.ygyno.2022.11.001

Figure 5 –

Figure 5 –

(A) Tumor vessels demonstrating disruption or bleeding were significantly higher in anti-VEGFR-2 treated mice compared to carboplatin (p=0.0138). (B) Tumor vessels capable of supporting flow at the time of the IVM observation showed statistically significant improvement in carboplatin (p=0.0069) and anti-PD-1 (p=0.0145) treatment groups compared to anti-VEGFR-2. (C) Blood flow velocity of tumor vessels and (D) wall shear stress showed no significant differences between groups. (n = 8–10 mice per group in 3 individual experiments)